RVL Pharmaceuticals PLC (NASDAQ:RVLP)
| 0.8301 BATS BZX Real-Time Price As of 11:45am ET |  -0.0299 / -3.48%Today’s Change | 0.72 Today|||52-Week Range 2.99 | -25.88% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $87.4M |
Company Description
RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.
Contact Information
RVL Pharmaceuticals Plc 400 Crossing Boulevard Bridgewater New Jersey 08807 |
Employees
Shareholders
| Individual stakeholders | 66.61% |
| Other institutional | 22.77% |
| Mutual fund holders | 2.60% |
Top Executives
| Brian A. Markison | Chairman, Chief Executive & Financial Officer |
| James Schaub | Chief Operating Officer & Executive Vice President |
| Sergio Alegre | Vice President-Global Compliance |
| Michael J. Depetris | Chief Accounting Officer |
| Jarret Miller | Executive Vice President-Human Resources |
